Viewing StudyNCT02462538



Ignite Creation Date: 2024-05-06 @ 7:06 AM
Last Modification Date: 2024-10-26 @ 11:44 AM
Study NCT ID: NCT02462538
Status: TERMINATED
Last Update Posted: 2022-03-03
First Post: 2015-05-18

Brief Title: Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK ALCL
Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Organization: Arbeitsgemeinschaft medikamentoese Tumortherapie

Key Dates - Follows AllAPIJSON File Order

Start Date: 2015-11-03
Start Date Type: ACTUAL
Primary Completion Date: 2021-11-03
Primary Completion Date Type: ACTUAL
Completion Date: 2021-11-03
Completion Date Type: ACTUAL
First Submit Date: 2015-05-18
First Submit QC Date: June 2 2015
Study First Post Date: 2015-06-04
Study First Post Date Type: ESTIMATED
Results First Submit Date: None
Results First Submit QC Date: None
Results First Post Date: None
Results First Post Date Type: None
Results First Post QC Date: None
Results First Post QC Date Type: None
Disp First Submit Date: None
Disp First Submit QC Date: None
Disp First Post Date: None
Disp First Post Date Type: None
Last Update Submit Date: 2022-02-15
Last Update Post Date: 2022-03-03
Last Update Post Date Type: ACTUAL